Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Parapoxvirus ovis immunomodulator formulations: BayerRecent Research Landscape

Immune evasion by self-antigens prevents effective therapeutic vaccination against cancers and chronic infections. These compositions engineer specific immunostimulatory pathways to override endogenous inhibitory signals and trigger targeted autoimmunity.

What technical problems is Bayer addressing in Parapoxvirus ovis immunomodulator formulations?

Insufficient endogenous immune response

(12)evidences

Weak endogenous immune responses limit the efficacy of therapeutic interventions against pathogens or tumors. Enhancing the magnitude of immune signaling overcomes systemic tolerance and therapeutic resistance.

Protein structural instability

(11)evidences

Pathological thrombus formation and rapid degradation of blood components during storage. Mitigating these risks prevents life-threatening vascular events and extends the viability of therapeutic blood products.